Abstract
Oritavancin is a semisynthetic lipoglycopeptide in clinical development for serious gram-positive infections. This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus.
MeSH terms
-
Acetamides / administration & dosage
-
Anti-Bacterial Agents / administration & dosage*
-
Aza Compounds / administration & dosage
-
Drug Synergism
-
Fluoroquinolones
-
Gentamicins / administration & dosage
-
Glycopeptides / administration & dosage*
-
Humans
-
Linezolid
-
Lipoglycopeptides
-
Methicillin Resistance
-
Microbial Sensitivity Tests / methods
-
Moxifloxacin
-
Oxazolidinones / administration & dosage
-
Polysorbates
-
Quinolines / administration & dosage
-
Rifampin / administration & dosage
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology
-
Staphylococcus aureus / drug effects*
-
Surface-Active Agents
-
Vancomycin Resistance
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Aza Compounds
-
Fluoroquinolones
-
Gentamicins
-
Glycopeptides
-
Lipoglycopeptides
-
Oxazolidinones
-
Polysorbates
-
Quinolines
-
Surface-Active Agents
-
Linezolid
-
oritavancin
-
Moxifloxacin
-
Rifampin